Immusoft
- Biotech or pharma, therapeutic R&D
Immusoft is developing B cells as protein biofactoires for sustained therapeutic protein delivery. Our approach is non-viral, has the capability of delivering large payloads, and is now undergoing clinical investigation in our lead indication, MPS I.